Spotlight on Gastroenterology

Credits: 0.25 CME
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Future Therapeutic Approaches
Miguel Regueiro, MD, AGAF, FACG, FACP
Vindico

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Future Therapeutic Approaches

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres Therapeutics, Takeda, UCB
  • Speakers Bureau: AbbVie, Janssen, Takeda
  • Unrestricted Educational Grants: AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres Therapeutics, Takeda, UCB
  • Speakers Bureau: AbbVie, Janssen, Takeda
  • Unrestricted Educational Grants: AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Gastroenterology Presentations

0.75 CME
Integrity Continuing Education, Inc.
The Dawn of a New Era: Emerging Therapeutic Strategies in the Diagnosis and Management of NASH

The Dawn of a New Era: Emerging Therapeutic Strategies in the Diagnosis and Management of NASH

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 1, 2020
Expires: July 1, 2021
45 minutes to complete

Accredited By

Target Audience

This educational activity addresses the needs of gastroenterologists, hepatologists, and other healthcare professionals involved in the diagnosis and treatment of nonalcoholic steatohepatitis (NASH).

Learning Objectives

  • Employ current epidemiologic and demographic data to enhance NASH identification
  • Apply liver biopsy and complementary noninvasive modalities for nonalcoholic fatty liver disease (NAFLD)/NASH diagnosis, staging, and monitoring
  • Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers
  • Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH

Activity Description

NAFLD affects 24% of the American population and is projected to be the cause of nearly 800,000 excessive liver deaths from 2015 to 2030. NASH, the aggressive form of NAFLD, is a growing cause of cirrhosis and hepatocellular carcinoma and increasingly an indicator for liver transplantation. Healthcare providers would benefit from education on current epidemiologic and demographic data to enhance NASH identification, along with information on the use of liver biopsy and complementary noninvasive modalities to diagnose, stage, and monitor NAFLD/NASH progression. There is currently no FDA-approved targeted treatment for NASH. However, promising agents are undergoing late-stage clinical trials, and providers must be brought up-to-date on recent safety and efficacy outcomes. Barriers to clinical trial enrollment must also be addressed. Understanding the disease pathophysiology that informs drug development will aid in applying these agents to practice should FDA approval be obtained. This educational activity will address these knowledge gaps among healthcare providers involved in the care of patients with NASH, and application of the knowledge gained will improve patient outcomes.

Faculty

Steven L. Flamm, MD
Professor of Medicine
Chief, Transplant Hepatology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Steven L. Flamm, MD
Consulting Fees: Intercept Pharmaceuticals
Contracted Research: Intercept Pharmaceuticals

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving CME Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 1, 2020 through July 1, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from Intercept Pharmaceuticals.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 1, 2020
Expires: July 1, 2021
45 minutes to complete

Accredited By

Target Audience

This educational activity addresses the needs of gastroenterologists, hepatologists, and other healthcare professionals involved in the diagnosis and treatment of nonalcoholic steatohepatitis (NASH).

Learning Objectives

  • Employ current epidemiologic and demographic data to enhance NASH identification
  • Apply liver biopsy and complementary noninvasive modalities for nonalcoholic fatty liver disease (NAFLD)/NASH diagnosis, staging, and monitoring
  • Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers
  • Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH

Activity Description

NAFLD affects 24% of the American population and is projected to be the cause of nearly 800,000 excessive liver deaths from 2015 to 2030. NASH, the aggressive form of NAFLD, is a growing cause of cirrhosis and hepatocellular carcinoma and increasingly an indicator for liver transplantation. Healthcare providers would benefit from education on current epidemiologic and demographic data to enhance NASH identification, along with information on the use of liver biopsy and complementary noninvasive modalities to diagnose, stage, and monitor NAFLD/NASH progression. There is currently no FDA-approved targeted treatment for NASH. However, promising agents are undergoing late-stage clinical trials, and providers must be brought up-to-date on recent safety and efficacy outcomes. Barriers to clinical trial enrollment must also be addressed. Understanding the disease pathophysiology that informs drug development will aid in applying these agents to practice should FDA approval be obtained. This educational activity will address these knowledge gaps among healthcare providers involved in the care of patients with NASH, and application of the knowledge gained will improve patient outcomes.

Faculty

Steven L. Flamm, MD
Professor of Medicine
Chief, Transplant Hepatology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Steven L. Flamm, MD
Consulting Fees: Intercept Pharmaceuticals
Contracted Research: Intercept Pharmaceuticals

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving CME Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 1, 2020 through July 1, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from Intercept Pharmaceuticals.

0.25 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Future Therapeutic Approaches

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Future Therapeutic Approaches

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres Therapeutics, Takeda, UCB
  • Speakers Bureau: AbbVie, Janssen, Takeda
  • Unrestricted Educational Grants: AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres Therapeutics, Takeda, UCB
  • Speakers Bureau: AbbVie, Janssen, Takeda
  • Unrestricted Educational Grants: AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Crohn’s Disease

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Crohn’s Disease

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA
  • Disclosures:
  • Royalty: SLACK Incorporated
  • Consulting Fee: AbbVie, Celgene, Cellcuetix, Endo Pharmaceuticals, Ferring, Gilead, Janssen, Lilly, Luitpold/American Regent, Merck, Morphic Therapeutic, Pfizer, Prometheus, Romark, Salix/Valeant, Shire, Takeda, UCB
  • Contracted Research: Celgene, Janssen, Salix/Valeant, Shire, UCB
  • Consulting Fee (paid to institution): Janssen, Pfizer, Takeda
  • Data and Safety Monitoring Board: Lilly
  • Author Honoraria: McMahon Publishing, UpToDate
  • Editor Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA
  • Disclosures:
  • Royalty: SLACK Incorporated
  • Consulting Fee: AbbVie, Celgene, Cellcuetix, Endo Pharmaceuticals, Ferring, Gilead, Janssen, Lilly, Luitpold/American Regent, Merck, Morphic Therapeutic, Pfizer, Prometheus, Romark, Salix/Valeant, Shire, Takeda, UCB
  • Contracted Research: Celgene, Janssen, Salix/Valeant, Shire, UCB
  • Consulting Fee (paid to institution): Janssen, Pfizer, Takeda
  • Data and Safety Monitoring Board: Lilly
  • Author Honoraria: McMahon Publishing, UpToDate
  • Editor Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Ulcerative Colitis

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Ulcerative Colitis

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC
  • Disclosures:
  • Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant
  • Speakers Bureau: AbbVie, UCB
  • Contracted Research: Pfizer, Takeda


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC
  • Disclosures:
  • Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant
  • Speakers Bureau: AbbVie, UCB
  • Contracted Research: Pfizer, Takeda


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Utilizing Therapeutic Drug Monitoring

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Utilizing Therapeutic Drug Monitoring

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty Member and Activity Co-chair

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Activity Co-chair

Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty Member and Activity Co-chair

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Activity Co-chair

Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Goals of Management of IBD

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Goals of Management of IBD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Jonathan A. Leighton, MD, FACG, AGAF, FASGE, FACP
Professor of Medicine, Division of Gastroenterology and Hepatology
Vice Chair, Department of Medicine
Mayo Clinic Arizona
Phoenix, AZ
  • Disclosures:
  • Consulting Fee: Olympus
  • Contracted Research: Pfizer, Theravance Biopharma
  • Advisory Board: Check-Cap


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the importance of adherence to established quality measures for IBD management for both providers and patients.
  • Evaluate the components of effective treat-to-target approach for patients with IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Jonathan A. Leighton, MD, FACG, AGAF, FASGE, FACP
Professor of Medicine, Division of Gastroenterology and Hepatology
Vice Chair, Department of Medicine
Mayo Clinic Arizona
Phoenix, AZ
  • Disclosures:
  • Consulting Fee: Olympus
  • Contracted Research: Pfizer, Theravance Biopharma
  • Advisory Board: Check-Cap


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the importance of adherence to established quality measures for IBD management for both providers and patients.
  • Evaluate the components of effective treat-to-target approach for patients with IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com